^
Association details:
Biomarker:KRAS G12C + TP53 mutation
Cancer:Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer

Published date:
02/17/2023
Excerpt:
Our findings indicated that, USH2A missense mutations and the KRASG12C mutation combined with TP53 mutation were associated with better efficacy and survival outcomes…
DOI:
https://doi.org/10.1631/jzus.B2200292